Abstract: The present disclosure relates to a roof rack foot assembly for a roof rack including a carrier member for carrying a crossbar of the roof rack, and a bracket. The bracket is configured for attachment to a fix point attachment position of a vehicle by use of at least one fixation member. The bracket includes an engagement portion and a seat portion for the carrier member.

Abstract: A roof rack foot for securing a cross bar to a roof of a vehicle. The roof rack foot includes a clamping portion and an adjustment mechanism. The adjustment mechanism includes an actuation element with an actuation device, and an engagement element. The actuation element is movably engaged with the engagement element in an engagement zone. The roof rack foot is configured to be secured to the roof or the cross bar by the clamping portion by operating the adjustment mechanism with the actuation device. The actuation device and the engagement zone are at least partially provided on opposite sides of the clamping portion in at least one operating condition of the roof rack foot.

Abstract: A roof rack foot for securing a cross bar to a roof of a vehicle, the cross bar having a bottom wall with a slot and a cavity for forming an abutment surface, the slot having a centerline, the roof rack foot having a supporting surface for supporting the bottom wall of the cross bar, a first and a second clamping portion for clamping the roof rack foot to the roof, the second clamping portion having an anchoring arm and configured to extend through the slot into the cavity and lock the cross bar to the supporting surface by engagement of the anchoring arm with the abutment surface. When the cross bar is locked to the roof rack foot, the anchoring arm stands upright on the abutment surface and at least partially extends away from the centerline of the cross bar at an extension angle.

Abstract: A roof rack foot for securing a cross bar to a roof of a vehicle, the cross bar having a bottom wall with a slot and a cavity for forming an abutment surface, the slot having a centerline, the roof rack foot having a supporting surface for supporting the bottom wall of the cross bar, a first and a second clamping portion for clamping the roof rack foot to the roof, the second clamping portion having an anchoring arm and configured to extend through the slot into the cavity and lock the cross bar to the supporting surface by engagement of the anchoring arm with the abutment surface. When the cross bar is locked to the roof rack foot, the anchoring arm stands upright on the abutment surface and at least partially extends away from the centerline of the cross bar at an extension angle.

Abstract: This invention relates to compounds that are selective inhibitors of Matrix Metalloprotease-12 (MMP-12), to cosmetic and pharmaceutical compositions containing them, and to their use in the prevention and/or treatment of ailments associated with MMP-12. Formula (I).

Abstract: This invention relates to compounds that are selective inhibitors of Matrix Metalloprotease-12 (MMP-12), to cosmetic and pharmaceutical compositions containing them, and to their use in the prevention and/or treatment of ailments associated with MMP-12. Formula (I).

Abstract: The present invention is related to a novel and improved process for the manufacture of compounds of formula (I) or salts thereof herein designated as benzylsulfonyl-Ser-X-4-amidinobenzylamide, wherein R is a C1 to C6 linear or branched aliphatic hydrocarbon chain optionally substituted with a C6 to C10 aromatic group.

Abstract: The present invention relates to the use of p-hydroxybenzylamine or a salt thereof as antimicrobial agent as well as to composition comprising said agent.

Abstract: The present invention is related to a novel and improved process for the manufacture of compounds of formula (I) or salts thereof herein designated as benzylsulfonyl-Ser-X-4-amidinobenzylamide, wherein R is a C1 to C6 linear or branched aliphatic hydrocarbon chain optionally substituted with a C6 to C10 aromatic group.

Abstract: The present invention relates to the use of p-hydroxybenzylamine or a salt thereof as antimicrobial agent as well as to composition comprising said agent.

Abstract: The present invention relates to the use of p-hydroxybenzylamine or a salt thereof as antimicrobial agent as well as to composition comprising said agent.

Abstract: The present invention relates to compositions comprising p-hydroxybenzylamine or a salt thereof and at least one preservative as well as to the use of p-hydroxybenzylamine or a salt thereof to boost the antimicrobial activity of at least one preservative.

Abstract: The present invention relates to the field of active compositions for use in cosmetic products for humans. More particularly, the present invention relates to a cosmetic composition comprising benzylsulfonyl-D-Ser-homoPhe-(4-amidino-benzylamide), or a salt thereof, and a polyalcohol. Moreover, it relates to the use of said composition for maintaining, restoring, and/or improving the skin hydration, and/or the transepidermal water loss level in human skin. The present invention further relates to the use of benzylsulfonyl-D-Ser-homoPhe-(4-amidino-benzylamide), or a salt thereof, in combination with a polyalcohol for the co-inhibition of both plasmin and urokinase activity in the skin and/or the scalp.

Abstract: The present invention describes a method for the synthesis of enantiomerically pure 3-amidinophenylalanine derivatives, which are used as pharmaceutically effective urokinase inhibitors, by starting from 3-cyanophenylalanine derivatives. The methods of manufacture comprising only one synthesis step lead to new intermediates, namely 3-hydroxyamidino- and 3-amidrazonophenylalanine derivatives. These intermediates or their acetyl derivatives can be reduced into the desired 3-amidino-phenylalanine derivatives under gentle conditions (H2 or ammonium formiate, Pd/C (approx. 10%), ethanol/water, room temperature, normal pressure or also H2, Pd/C, AcOH or HCl/ethanol, 1-3 bar) in excellent yields and in an enantiomeric excess of up to 99.9%.

Abstract: Topical composition for use especially as a skin lightener, characterized in that it contains an effective amount of at least one compound of general formula (I) or a mixture of such compounds and/or an acid addition salt thereof: in which X is NH or a direct bond and n is 2, 3 or 4, preferably 2 or 3, and its use for lightening skin colour, for depigmenting liver spots and for evening out non-uniformities in skin colouration. The invention further relates to dermatologically effective compositions containing at least one disulfide of general formula (I) and at least one additional skin care ingredient.

Abstract: The present invention relates to the use of tripeptide derivatives for tightening, firming and/or moisturizing skin. Furthermore, the invention relates to a method for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue and/or proteoglycans by fibroblasts and/or keratinocytes such as in particular the synthesis of Hyaluronic acid and/or of the proteoglycans Decorin and/or Lumican.

Abstract: The present invention describes a method for the synthesis of enantiomerically pure 3-amidinophenylalanine derivatives, which are used as pharmaceutically effective urokinase inhibitors, by starting from 3-cyanophenylalanine derivatives. The methods of manufacture comprising only one synthesis step lead to new intermediates, namely 3-hydroxyamidino- and 3-amidrazonophenylalanine derivatives. These intermediates or their acetyl derivatives can be reduced into the desired 3-amidino-phenylalanine derivatives under gentle conditions (H2 or ammonium formiate, Pd/C (approx. 10%), ethanol/water, room temperature, normal pressure or also H2, Pd/C, AcOH or HCl/ethanol, 1-3 bar) in excellent yields and in an enantiomeric excess of up to 99.9%.

Abstract: The present invention describes a method for the synthesis of enantiomerically pure 3-amidinophenylalanine derivatives, which are used as pharmaceutically effective urokinase inhibitors, by starting from 3-cyanophenylalanine derivatives. The methods of manufacture comprising only one synthesis step lead to new intermediates, namely 3-hydroxyamidino- and 3-amidrazonophenylalanine derivatives. These intermediates or their acetyl derivatives can be reduced into the desired 3-amidino-phenylalanine derivatives under gentle conditions (H2 or ammonium formiate, Pd/C (approx. 10%), ethanol/water, room temperature, normal pressure or also H2, Pd/C, AcOH or HCl/ethanol, 1-3 bar) in excellent yields and in an enantiomeric excess of up to 99.9%.

Abstract: The compounds of formula (I) wherein X represents a bond or NH—CH(C?O)—(CH2)3+n—NH—R5, n represents 0, 1 or 2, R1, R4 and R5—independently from each other—represent hydrogen, possibly substituted C1-C6-alkyl, amidino or tetra-C1-C6-alkylamidinium, R2 represents hydrogen or possibly substituted C1-C6-alkyl or R1 and R2 together with the residue to which they are bound represent a 5- to 7-membered, saturated ring, R3 represents C1-C12-alkoxy, C1-C12-alkylamino, possibly substituted aryl-C1-C6-alkylamino, possibly substituted heteroaryl-C1-C6-alkylamino, possibly substituted aryl-C1-C6-alkoxy or possibly substituted heteroaryl-C1-C6-alkoxy, and R6 represents hydrogen or, when n is 1, also amino or together with R1 and the residue to which R6 and R1 are bound a 5- to 7-membered, saturated ring, as well as their physiologically acceptable salts are new.

Abstract: The present invention describes a method for the synthesis of enantiomerically pure 3-amidinophenylalanine derivatives, which are used as pharmaceutically effective urokinase inhibitors, by starting from 3-cyanophenylalanine derivatives. The methods of manufacture comprising only one synthesis step lead to new intermediates, namely 3-hydroxyamidino- and 3-amidrazonophenylalanine derivatives. These intermediates or their acetyl derivatives can be reduced into the desired 3-amidino-phenylalanine derivatives under gentle conditions (H2 or ammonium formiate formate, Pd/C (approx. 10%), ethanol/water, room temperature, normal pressure or also H2, Pd/C, AcOH or HCl/ethanol, 1-3 bar) in excellent yields and in an enantiomeric excess of up to 99.9%.